



May 19, 2026

Listing Department
BSE LIMITED
P J Towers, Dalal Street,
Mumbai-400 001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C/1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: ZYDUSLIFE

Re: **Investor Presentation**

Ref.: **Disclosure under regulation 30 read with regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")**

Dear Sir,

Pursuant to the provisions of regulation 30 read with regulation 46 of the Listing Regulations, please find attached the Investor Presentation on the audited financial results for the quarter / year ended on March 31, 2026.

Please find the same in order.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL
NARENDRA
SONI

Digitally signed by
DHAVAL NARENDRA
SONI
Date: 2026.05.19
14:17:38 +05'30'

DHAVAL N. SONI
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Zydus Lifesciences Limited

Earnings Presentation: Q4 & Full Year FY26

19th May, 2026

Disclaimer and Safe Harbor Statement

- *THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY"). The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares. This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.*
- *By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment income (vi) cash flow projections etc.*
- *The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates. This document is just a Presentation and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the Company's equity shares. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from. This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This document and its contents should not be forwarded or delivered or transmitted in any manner to any person other than its intended recipient, and should not be reproduced in any manner whatsoever.*

Q4 FY26: At a Glance

Revenues from Operations

Rs. 75,870 mn
 ▲ 16% YoY

R&D

Rs. 6,982 mn
 9.2% of revenues


EBITDA & Margin %

Rs. 25,544 mn
 33.7% of revenues
 ▲ 20% YoY

Net Profit ex. Exceptional

Rs. 15,929 mn
 ▲ 15% YoY

Business-wise Sales Break-up (Rs. mn) and YoY Growth



Highlights of Q4 FY26


- ❑ Total revenues grew **16% YoY**.
- ❑ Within **Pharmaceutical** business,
 - **India branded** formulations **sustained** the growth momentum and **outpaced** the market growth for yet another quarter.
 - **North America** formulations business **grew sequentially** led by **base business volume expansion**, **new launches** and **sustained traction** in **rare disease** portfolio.
 - **International Markets** business **further accelerated** its growth trajectory across regions.
- ❑ **Consumer Wellness** business continued to hold **dominant market share** in **key brands in India**; **International business**, including **CCL** business delivered **robust performance** on a like-to-like basis.
- ❑ EBITDA margin stood at **33.7%**, **up 110 bps** YoY.
- ❑ Capex (organic) for the quarter: **Rs. 3,577 mn**.
- ❑ Net Debt: Rs. **43,050 mn** (as at 31-Mar'26)

Key Board Meeting Updates


- ❑ The Board approved **buy-back** of upto **Rs. 11,000 mn** at **Rs. 1,150 per equity share** (16% premium to closing share price of 18th May 2026).

Key Financial Metrics (1/2)


Total Revenues (Rs. mn)




Gross Profit (Rs. mn) and Gross Margin %



Total R&D (Rs. mn) and % to Revenues




EBITDA (Rs. mn) and EBITDA Margin %




Key Financial Metrics (2/2)


PAT ex. Exceptional (Rs. mn)




Organic Capex (Rs. mn)



Net Debt to EBITDA (x)




Net Working Capital* (Rs. mn)




*Net working capital includes Inventory, Trade receivables and Trade payables.

Sustained market outperformance led by chronic portfolio


India Formulations Sales (Rs. mn)



Q4 FY26 Revenue Contribution



India Formulations Sales (Rs. mn)



Q4 FY26 Gr.

YoY

14.0%

QoQ

2.5%

FY26 Gr.

10.9%

Brand building - a key growth driver

of Brands

1000+

10

500 to 1000


24

250 to 500

35

Brand Value (Rs. Mn)*

Therapy-wise Break-up*



Highlights for the quarter


- Branded business grew **faster** than the market with **15% YoY growth**.
- Outperformed IPM** in **key therapies** of Cardiology, Respiratory, Dermatology and in super specialty areas of Oncology and Nephrology.
- On the Super Specialty front, continued to retain **leadership** position in **Oncology** therapy.
- Share of **Chronic** portfolio has **gone up** consistently over the years and stood at **46.3%***, an **improvement** of **620 bps** over the last 3 years.
- Launched **Tishtha™**, world's **first biosimilar** of **Nivolumab**.
- Launched **Anyra™**, country's **first indigenously developed biosimilar** of **Aflibercept 2 mg**
- Launched **Semaglutide** injection under three brands **SEMAGLYN™**, **MASHEMA™**, and **ALTERME™**.

*Source: IQVIA MAT March 26


Base business volume expansion and new launches drove the growth

North America Formulations Sales (Rs. mn)

Q4 FY26 Revenue Contribution



North America Formulations Sales (Rs. mn)



Q4 FY26 Gr.

YoY

-5.7%

QoQ

5.3%

FY26 Gr.




5.7%

Continued investment to build the generics pipeline

ANDA filings and approvals - Q4 FY26

ANDA filings and approvals - FY26

ANDA filings and approvals - Cumulative



^ includes 6 tentative approvals in FY26 and 26 on a cumulative basis.

Highlights for the quarter

US Generics

- Ranked **3rd** among US generic companies based on **generic TRx***. This represents a **gain of 2 position** over last 4 years.
- Launched **6 new products**.
- Filed **3 ANDAs** and received **approval** for **9 ANDAs**.

US Specialty


- In April 2026, **filed 2 new products dossiers** through 505(b)(2) route.
- Signed definitive agreement to acquire **Assertio Holdings Inc.**, a US based pharmaceutical company focused on **specialty** and **oncology supportive-care** therapy for a consideration of US\$ 166 mn.

US Orphan and Rare Diseases


- Launched **Zycubo®** (copper histidinate) for ultra-rare **Menkes disease**.

Strong growth : Resilient demand across markets


EM & EU Formulations Sales
(Rs. mn)



Q4 FY26 Revenue Contribution



EM & EU Formulations Sales (Rs. mn)



Q4 FY26 Gr.



FY26 Gr.


39.9%

Highlights for the quarter


- Growth was **broad based** in both **Emerging markets** and **Europe** driven by **strong demand** and **focused execution**.
- In **Emerging Markets**, adopted a **focused, therapy led** approach, tailoring the offerings to meet the **needs** of **specific markets** and in turn, built a **more agile, market responsive** portfolio.
- In **Europe**, focus remains on **broadening** the **portfolio** and **enhance** the **market coverage**.

Strengthening international presence through CCL acquisition


Consumer Wellness Sales (Rs. mn)




Q4 FY26 Revenue Contribution



Consumer Wellness Sales (Rs. mn)



Q4 FY26 Gr.



FY26 Gr.

46.0%

Highlights for the quarter

- In domestic business, retained **leadership position** across most product categories.
- Domestic business** grew by **1.7% y-o-y**. **Seasonal brands** declined by **9.8% y-o-y**, whereas the **Skin & hair care** brands and **food & nutrition** brands registered **39.7%** and **9.4% y-o-y** growth respectively.
- International business, including CCL** business, delivered **31.4%** growth on like-to-like basis.

Key brands in India continued to hold dominant market share

Brand Name	Glucan-D Instant Energy	nycil	Sugar Free	everyuth naturals	Complan	Nutralite	RiteBite NUTRITION BAR	MAX PROTEIN
Market Share#	58.9%	33.2%	96.1%	8.0%	4.0%	NA	NA	NA
Market Rank	1	1	1	5	4	1##	1##	1##
				Facial Cleansing * 8.0%		Fat spread NA	Nutrition & Protein Bar NA	Protein Cookies & Chips NA
				Scrub 48.6%		Dairy NA	Other Nutrition Products NA	
				Peel Off 75.5%				

NCE Research

- Desidustat tablets, which was licensed to China Medical System Holdings in 2020, received approval from the Chinese regulator for the treatment of renal anemia.
- USFDA granted ODD status to Desidustat for the treatment of sickle cell disease.
- Received approval from DCGI for Zintrodiazine, a novel anti-malarial candidate, to conduct two Phase III clinical trials in India in patients with uncomplicated malaria due to both Plasmodium falciparum and Plasmodium vivax.

Biotech R&D

- Initiated Phase III clinical trials for the second biosimilar antibody drug conjugate in India.
- On novel biologics front, Initiated Phase I clinical trials for one candidate, and pre-clinical studies for another candidate in India.
- On the global development front, successfully completed clinical development of an in-licensed Pembrolizumab biosimilar candidate FYB206 for the US market.

US Specialty and 505(b)(2) Initiatives

- Entered into an agreement with PRG S&T to license its investigational molecule Progerinin (SLC-D011) for HGPS.

Zydus at a Glance

+\$3
bn

Global Revenues¹

3rd

Largest generic Co. in US
in terms of prescription³

8

R&D Centers
For NCE, APIs, Generics, Vaccines
Biosimilars, Wellness and Med-tech
products

>50%

Revenues from Branded
Business (Pharmaceutical,
Wellness and Med -Tech)

Among
Top 3

In ~55% of product
families marketed in US⁴

1st

Approved product for
MASH in India - (Bilypsa[®] -
Saroglitazar)

\$10.6
bn

Market Capitalization²

7

Brands among Top
300 in India⁵

1st

OSD formulation for anemia
associated with CKD –
Oxemia[™] (Desidustat)

43

Mfg. sites having
capabilities across
dosage forms

>29 K

Zydans globally incl.
>1500 scientists (R&D)

1st

Biosimilar of Nivolumab
in the world - Tishtha[™]
Launched in India

1. In FY26, assuming exchange rate of Rs. 88.33 per USD
2. As on 18th May, 2026, exchange rate of Rs. 96.26 per USD
3. IQVIA MAT March 2026 TRx

4. IQVIA MAT March 2026 TRx
5. As per IQVIA MAT March 2026

S&P Global



Strong Category: An ESG leader who demonstrates strong track record in managing material ESG risks through a robust risk management framework



The ESG Risk Rating improved from 29.5 (Core Framework) to **28.4 (Comprehensive Framework)**, placing it in the **“Medium Risk” category**

- ZLL is ranked among the **top 10%** in the pharmaceutical industry **by S&P Global**, based on the **Corporate Sustainability Assessment (CSA) Score**.
- ZLL has been included in the **Dow Jones Best in Class (DJBIC) Emerging Markets Index**, positioning Zydus among the **Emerging Best-in-Class** companies globally.



Climate Change (GHG Emissions)



 **Net Carbon Neutral** by 2035

 **50% energy requirements from renewable sources** by 2030

 **37% of renewable energy** in the total energy mix

 **74% of renewable energy target achievement** by FY2026



Water Management



 **Net Water Neutral** by 2028

 Creation of water recharge structures in progress

 **>66% recycle and reuse** of treated wastewater



Waste Management



 **Waste disposal via co-processing up 40%** for India operations by 2026

 **34% waste disposal via co-processing** FY2026

 **85% target achievement** by FY2026

Consolidated Financial Performance (reported)

Rs. mn	Q4 FY26	Q4 FY25	YoY gr.	Q3 FY26	QoQ gr.	FY26	FY25	YoY gr.
Total Income from Ops.	75,870	65,279	16.2%	68,645	10.5%	2,71,484	2,32,415	16.8%
Gross Contribution (GC)	56,107	48,308	16.1%	50,282	11.6%	1,98,558	1,69,035	17.5%
Gross Margin %	74.0%	74.0%		73.2%		73.1%	72.7%	
Employee benefits expenses *	11,298	8,695	29.9%	10,235	10.4%	39,784	32,896	20.9%
R&D expenses	6,982	4,799	45.5%	6,074	14.9%	22,732	18,555	22.5%
<i>HR Cost</i>	1,090	1,019	7.0%	1,162	-6.2%	4,395	3,910	12.4%
<i>Opex</i>	5,892	3,780	55.9%	4,912	20.0%	18,337	14,645	25.2%
Other operating expenses *	18,732	13,165	42.3%	17,453	7.3%	64,096	48,633	31.8%
Net (gain)/loss on foreign currency transactions	-6,449	394	-1736.8%	-1,644	-292.3%	-12,805	-1,634	-683.7%
EBITDA	25,544	21,255	20.2%	18,164	40.6%	84,751	70,585	20.1%
EBITDA Margin %	33.7%	32.6%		26.5%		31.2%	30.4%	
Other Income	1,342	806	66.5%	1,114	20.5%	5,095	2,695	89.1%
Finance cost	1,230	766	60.6%	1,299	-5.3%	4,389	1,659	164.6%
Depreciation and amortization	5,084	2,379	113.7%	3,596	41.4%	14,080	9,158	53.7%
PBT before exceptional items	20,572	18,916	8.8%	14,383	43.0%	71,377	62,463	14.3%
Exceptional Expenses/ (Incomes)	3,975	2,196	81.0%	849	368.2%	5,166	2,196	135.2%
Profit before Tax	16,597	16,720	-0.7%	13,534	22.6%	66,211	60,267	9.9%
Tax expenses	3,184	4,232	-24.8%	3,883	-18.0%	15,947	14,119	12.9%
Share of profit from JVs	-3	-51	94.1%	578	-100.5%	971	578	68.0%
Profit/(loss) from discontinued ops. #	-	-		-		-	-	
Minority Interest	685	728	-5.9%	-192	456.8%	835	1,471	-43.2%
Reported Net Profit	12,725	11,709	8.7%	10,421	22.1%	50,400	45,255	11.4%

* Excludes Research related expenses

Details of Exchange Rate Fluctuations

Rs. mn	Q4 FY26	Q4 FY25	YoY gr. %	FY26	FY25	YoY gr. %
A. On operating transactions (above EBITDA line)	-6,052	504	-1300.8%	-11,976	-1,451	-725.2%
a. Included in COGS	398	110	262%	830	183	353.7%
b. Part of other operating expenses (shown separately)	-6,449	394	-1737%	-12,805	-1,634	-683.7%
Total Exchange Rate Fluctuations ('+' = loss, '-' = gain)	-6,052	504	-1300.8%	-11,976	-1,451	-725.2%

Thank you

For any queries, please contact
Arvind Bothra
Arvind.Bothra@zyduslife.com
+91-79-48040969

For more information, please visit:
 www.zyduslife.com

 www.linkedin.com/company/zyduslife



Registered Office:

Zydus Corporate Park, Scheme No. 63, Survey No. 536,
Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
Sarkhej-Gandhinagar Highway,
Ahmedabad – 382 481
Gujarat, India